What, who and when? Incorporating a discrete choice experiment into an economic evaluation

Health Economics Review

Table 6 WTP estimates (£) at 24-month follow-up and Net Benefit analysis

		All Medman trial participants			Trial groups			Intervention subgroups
		Intervention and control together	P-val^a Vs. Intervention	P-val^a Vs. Control	Intervention	Control	P-val^a	Intervention still receiving at 24 months	Intervention not receiving at 24 months	P-val^a
Willingness to pay (WTP) when moving from ‘Medicines review by GP only’ to ‘Medicines review by GP & Pharmacist’	mean	−26.475	<0.01	<0.01	3.52	−56.47	<0.01	41.55	−34.25	<0.01
	SD	10			1.17	18.83		13.85	11.42
Difference in societal costs from Tables 1 and 2		11.99			−11.20	+35.20		−36.73	+16.08
Net Benefit (NB)^b	mean	−38.47	0.44	0.30	14.72	−91.67	<0.01	78.29	−50.33	<0.01
Net Benefit (NB)^b	SD	229.11			1620.60	1167.68		1706.09	1528.41

^a Differences between groups at 24-month follow-up were tested using Mann–Whitney test statistics. ^b NB was calculated as: (WTP at 24-month follow-up, from DCE patient survey data; see Table 5) – (difference in society costs, from Medman Trial data see Tables 1 and 2)

ISSN: 2191-1991